Ensoma Alternatives & Competitors
12 companies similar to Ensoma — The future of medicine lies within us.
Companies similar to Ensoma
Thymmune Therapeutics
Biotech firm developing thymic cell therapies to restore immune function using machine lea...
Cambridge, United States
Modalis Therapeutics
Modalis is an emerging biotech company that develops therapeutics using CRISPR based techn...
Cambridge, United States
Capstan Therapeutics
Advancing cell engineering to develop therapeutics for a broad range of diseases
Garuda Therapeutics
Creating off-the-shelf, long-term durable blood stem cell therapies
Cambridge, United States
Track all Ensoma competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Guardant Health
Conquering Cancer With Data
Palo Alto, United States
Chameleon Biosciences, Inc.
Saving children's lives, one genetic disease at a time.
Tessera Therapeutics
Pioneering the future of genetic medicine with the power to rewrite the genome and cure di...
Artisan Biomed
Unraveling the African Genome to transform health care
South Africa
Kernal Biologics
KernalBio creates mRNA therapies that instruct specific cells on how to make their own med...
Cambridge, United States
Axovia Therapeutics
Driving gene therapy breakthroughs to develop transformative AAV treatments for patients w...
London, United Kingdom
Interius BioTherapeutics
Interius is developing new ways to engineer cells inside the human body, right where they...
Philadelphia, United Stat...
Mammoth Biosciences
Improving lives by reading and writing the code of life.
Brisbane, United States
About Ensoma
Ensoma, established in 2019, is pioneering a transformative approach in the Biotechnology, Health and Wellness, and Life Sciences sectors. Operating from the United States, Ensoma focuses on developing one-time in vivo treatments that aim to precisely engineer blood and immune cells to combat diseases intrinsically. Wi...
In Vivo Hematopoietic Stem Cell Engineering, Gene Therapy Development, Delivery System for Genetic Modifications
Patients with Hematologic Disorders, Healthcare Providers, Pharmaceutical Researchers, Biotech Investors
Genomic Medicine, In Vivo Treatments, Gene Modification, Immune Cell Engineering, Blood Cell Engineering, Engenious Vectors, Next-generation Therapies, One-time Treatments, Non-myeloablative Conditioning, Outpatient Healthcare, Off-the-shelf Biologics, Rare Disease Treatment, Precision Medicine, Genetic Engineering
B2B, B2D
Licensing, Product Sales, Service Fee
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Ensoma and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Ensoma on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
